BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19774949)

  • 1. Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer.
    Kansakar E; Chang YJ; Mehrabi M; Mittal V
    Am Surg; 2009 Sep; 75(9):785-9; discussion 789. PubMed ID: 19774949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of estrogen receptor and progesterone receptor in colorectal cancer: a quantitative study].
    Zhou ZW; Wan DS; Wang GQ; Pan ZZ; Lu HP; Gao JH; Ding PR
    Ai Zheng; 2004 Jul; 23(7):851-4. PubMed ID: 15248927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
    Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of estrogen receptor, progesterone receptor, and insulin-like growth factor receptor-1 and of MIB-1 in patients with recurrent pleomorphic adenoma of the parotid gland.
    Glas AS; Hollema H; Nap RE; Plukker JT
    Cancer; 2002 Apr; 94(8):2211-6. PubMed ID: 12001119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
    Liu R; Pu DM; Cheng YX; Yin L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target.
    Coyle YM; Xie XJ; Hardy DB; Ashfaq R; Mendelson CR
    Cancer Lett; 2007 Dec; 258(2):253-61. PubMed ID: 17950525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of the functional status of estrogen receptor cascade in breast cancer.
    Kolár Z; Ehrmann J; Dusková M
    Neoplasma; 1998; 45(2):83-7. PubMed ID: 9687888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.
    de la Torre NG; Buley I; Wass JA; Turner HE
    Endocr Relat Cancer; 2006 Sep; 13(3):931-44. PubMed ID: 16954441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
    Lee P; Rosen DG; Zhu C; Silva EG; Liu J
    Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
    Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
    Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors.
    Lewy-Trenda I; Wierzchniewska-Ławska A
    Pol J Pathol; 2002; 53(3):129-32. PubMed ID: 12476614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors.
    Del Carmen MG; Smith Sehdev AE; Fader AN; Zahurak ML; Richardson M; Fruehauf JP; Montz FJ; Bristow RE
    Cancer; 2003 Oct; 98(8):1658-63. PubMed ID: 14534882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients.
    Lieto E; Ferraraccio F; Orditura M; Castellano P; Mura AL; Pinto M; Zamboli A; De Vita F; Galizia G
    Ann Surg Oncol; 2008 Jan; 15(1):69-79. PubMed ID: 17896140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.
    Xia G; Kumar SR; Hawes D; Cai J; Hassanieh L; Groshen S; Zhu S; Masood R; Quinn DI; Broek D; Stein JP; Gill PS
    J Urol; 2006 Apr; 175(4):1245-52. PubMed ID: 16515971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model].
    Tian XS; Zhou WH; Wu GJ; Sun JZ; Cong MH
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):559-63. PubMed ID: 18649774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.